What's Happening?
Nektar Therapeutics has initiated Phase 3 trials for rezpegaldesleukin, a novel regulatory T-cell biologic, in patients with moderate-to-severe atopic dermatitis. The ZENITH AD program includes three global, randomized, double-blind, placebo-controlled
trials targeting patients aged 12 and older. Rezpegaldesleukin aims to restore immune balance by stimulating regulatory T-cells, offering a potential new treatment option for autoimmune disorders. Initial data from the trials is expected in mid-2028, with a Biologics License Application submission targeted for 2029.
Why It's Important?
Atopic dermatitis affects millions in the U.S., with many patients experiencing inadequate disease control with current therapies. Rezpegaldesleukin represents a promising advancement in treatment, potentially offering more durable and effective disease management. The success of these trials could lead to a new standard of care for atopic dermatitis and other autoimmune conditions, impacting patient outcomes and healthcare practices.
What's Next?
As the Phase 3 trials progress, Nektar Therapeutics will focus on gathering robust data to support regulatory submissions in the U.S. and Europe. The company also plans to initiate a Phase 3 trial for alopecia areata in 2027, expanding the potential applications of rezpegaldesleukin. Stakeholders, including healthcare providers and patient advocacy groups, will be monitoring the trials closely, as positive results could significantly influence treatment paradigms.
